Phacilitate Leaders World

Sponsors & Exhibitors

Avalon

Avalon GloboCare Corp. (NASDAQ : AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promote and empower high impact, transformative biotechnology and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab."

In addition, AVCO provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. AVCO, via its subsidiary “Avalon RT9 Properties, LLC”, also engages in the acquirement and management of healthcare facility.

Through its U.S. subsidiary, GenExosome Technologies Inc., AVCO further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.

Visit Website
View all Sponsors & Exhibitors
Loading
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK